Revenue of $178.06M (-6.7% Y/Y) beats by $6.09M.
Thursday, August 1, 2019
Blueprint Medicines EPS misses by $0.09, beats on revenue
Blueprint Medicines (NASDAQ:BPMC): Q2 GAAP EPS of -$2.04 misses by $0.09.
Revenue of $5.11M (-87.7% Y/Y) beats by $3.72M.
Stericycle EPS misses by $0.27, beats on revenue
Stericycle (NASDAQ:SRCL): Q2 Non-GAAP EPS of $0.56 misses by $0.27; GAAP EPS of -$0.33 misses by $0.72.
Revenue of $845.8M (-4.2% Y/Y) beats by $1.85M.
Adaptimmune EPS beats by $0.29, misses on revenue
Adaptimmune (NASDAQ:ADAP): Q2 GAAP EPS of -$0.07 beats by $0.29.
Revenue of $0.2M (-97.8% Y/Y) misses by $1.72M.
Abiomed sinks 15% premarket on lowered guidance
Abiomed (ABMD) Q2 results: Revenues: $207.7M (+15.4%).
Impella pump sales: $199.9M (+15.1%).
Net Income: $88.9M (-1.3%); EPS: $1.93 (-1.0%); Non-GAAP EPS: $1.00; CF Ops: $64.6M.
FY 2020 Guidance: Revenue: $885M – 925M from $900M – 945M.
Shares are down 15% premarket.
Previously: Abiomed EPS beats by $0.01, misses on revenue (Aug. 1)
Intellia Therapeutics EPS beats by $0.05, beats on revenue
Intellia Therapeutics (NASDAQ:NTLA): Q2 GAAP EPS of -$0.56 beats by $0.05.
Revenue of $11.12M (+44.8% Y/Y) beats by $3.97M.
Exelixis teams up with Aurigene in oncology and inflammatory disorders
Exelixis (NASDAQ:EXEL) inks an exclusive collaboration, option and license agreement with Dr. Reddy’s Laboratories (NYSE:RDY) subsidiary Aurigene Discovery Technologies Limited under which it will have the option to in-license up to six programs in oncology and inflammatory diseases.
Under the terms of the deal, EXEL will pay $10M upfront for exclusive options to license three pre-existing Aurigene programs. The parties will initiate three new Aurigen-led drug discovery programs on mutually agreed-upon targets for option payments of $2.5M per program. EXEL will contribute research funding on all six and will have the opportunity to exercise its exclusive option for each program up until the time of IND acceptance (regulatory sign-off to start clinical studies). If EXEL exercises an option, it will pay Aurigene the option fee and will take over clinical development, commercialization and global manufacturing. Aurigene will also be eligible for milestones and royalties on net sales while retaining development and commercialization rights in India and Russia.
Subscribe to:
Posts (Atom)